News
Five IDIBELL researchers star in the Women of Science section of the television program Aula L’H
The Aula L’H program on L’Hospitalet digital television, specialized in education, together with the Institut Bellvitge and IDIBELL, have carried out, throughout the 2021-22 academic year, a complete edition of the Women of Science section, entirely dedicated to disseminating the research work, the research career and the personality of five IDIBELL scientists.
Validated a tool that assesses the risk of sudden death due to a heart disease
Twenty-nine reference centers from the United States, Canada, the Netherlands, Italy, France, and Spain, including IDIBELL, have participated in an international multicenter study that validated a model for predicting the risk of ventricular arrhythmias and sudden death in arrhythmogenic cardiomyopathy of the right ventricle (ARVC).
A generic antiviral could improve the life expectancy of patients with a rare disease without a cure
IDIBELL and Hospital de Bellvitge are studying the efficacy of Efavirenz, an antiretroviral against HIV, for the treatment of Niemann Pick type C in a clinical trial.
Two out of Three Women Between 30 and 49 Years of Age Have Never Been Screened for Cervical Cancer
A new study produces comparable estimates of screening coverage for 202 countries and territories
AtG Therapeutics completes a seed financing round raising more than half a million euros
The spin-off that emerged from IDIBELL and the Catalan Institute of Oncology is developing new therapeutic alternatives for advanced cancers and a screening system for these patients.
A model that improves screening of colorectal cancer has been developed
The study, led by researchers from IDIBELL, ICO and Hospital Clínic-IDIBAPS, analyzes the genetic variants associated with the risk of developing the cancer and should make it possible to reduce the number of unnecessary colonoscopies.
A Josep Maria Aran’s project financed by CaixaResearch Validate grants
These grants promote the creation of new products and companies in life sciences and health, as well as help transfer the research results to society and the market.